Search Result

Pathways Recommended:	Membrane Transporter/Ion Channel

Results for "

Renal outer medullary potassium channel (ROMK)

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Potassium Channel (10) Reference Standards (1)
By Research Areas:	Cardiovascular Disease (3) Metabolic Disease (1) Neurological Disease (2)

Inhibitors & Agonists

Peptides

Targets Recommended: Potassium Channel Na+/K+ ATPase

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-108585A

VU591	Potassium Channel	Neurological Disease
VU591 is a potent, selective renal outer medullary potassium channel (ROMK or Kir1.1) inhibitor, with an IC₅₀ of 0.24 μM. VU591 can be used for neurological research with HY-108585 (the equivalent of VU591 hydrochloride) .

HY-108595

VU590 2 Publications Verification	Potassium Channel	Others
VU590 is a potent and moderately selective ROMK (Kir1.1) inhibitor, with an IC₅₀ of 290 nM. VU590 also inhibits Kir7.1, with an IC₅₀ of 8 μM. VU590 is not a good probe of ROMK function in the kidney .

HY-108585

VU591 hydrochloride	Potassium Channel	Neurological Disease
VU591 hydrochloride is a potent, selective renal outer medullary potassium channel (ROMK or Kir1.1) inhibitor, with an IC₅₀ of 0.24 μM. VU591 hydrochloride can be used for neurological research with HY-108585A (the equivalent of VU591 hydrochloride) .

HY-132201

MK-8153	Potassium Channel	Metabolic Disease
MK-8153 is a potent, selective and orally active inhibitor of **renal outer medullary potassium channel (ROMK), with IC₅₀*s of 5 nM, 34 μM for ROMK* electrophysiology (EP) and hERG EP, respectively. MK-8153 can be used as the diuretic/atriuretic .

HY-124687

ROMK-IN-32	Potassium Channel	Cardiovascular Disease
ROMK-IN-32 is a renal outer medullary potassium channel (ROMK) inhibitor with an IC₅₀ of 35 nM. ROMK-IN-32 also inhibits hERG with an IC₅₀ of 22 μM .

HY-P1403

Tertiapin LQ	Potassium Channel	Others
Tertiapin LQ is a specific and reversible renal outer medullary potassium ROMK1 (Kir1.1) channel inhibitor .

HY-162555

BMS-986308	Potassium Channel	Cardiovascular Disease
BMS-986308 is a selective and orally active **renal outer medullary potassium (ROMK) channel** inhibitor. BMS-986308 is selective for ROMK over hERG. BMS-986308 can be used for heart failure research .

HY-123803

PF-06807656	Potassium Channel	Cardiovascular Disease
PF-06807656 is a selective **renal outer medullary** potassium channel (ROMK or Kir1.1) inhibitor. PF-06807656 has an IC₅₀ of 61 nM against hROMK in patch-clamp assays. PF-06807656 exhibits high selectivity for inhibiting rat ROMK and is insensitive to N171D pore mutations. PF-06807656 may be used in cardiovascular disease research .

HY-110076

VU590 dihydrochloride	Potassium Channel	Others
VU590 dihydrochloride is a potent and moderately selective ROMK (Kir1.1) inhibitor, with an IC₅₀ of 290 nM. VU590 also inhibits Kir7.1, with an IC₅₀ of 8 μM. VU590 dihydrochloride is not a good probe of ROMK function in the kidney .

HY-108595R

VU590 (Standard)	Reference Standards Potassium Channel	Others
VU590 (Standard) is the analytical standard of VU590 (HY-108595). This product is intended for research and analytical applications. VU590 is a potent and moderately selective ROMK (K_ir1.1) inhibitor, with an IC₅₀ of 290 nM. VU590 also inhibits K_ir7.1, with an IC₅₀ of 8 μM. VU590 is not a good probe of ROMK function in the K_idney .

Cat. No.	Product Name	Target	Research Area

HY-P1403

Tertiapin LQ	Potassium Channel	Others
Tertiapin LQ is a specific and reversible renal outer medullary potassium ROMK1 (Kir1.1) channel inhibitor .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

MedchemExpress Validation 03

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred

MedchemExpress Validation 04

MedchemExpress Validation

We use cookies

MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Privacy and Cookie Policy

Name
Email *

	Sorry, but the email address you supplied was invalid.